InvestSMART

Invion Limited (ASX:IVX)

ALERT: Price-sensitive ASX Announcement for IVX
Current share price for IVX : $0.037 -0.003 (-7.50%)+
Announcement
Release
31 Jul 2026 1:03PM
Price at Release
$0.040
Full Release
download
Summary
Invion Limited reported significant progress in its Quarterly Activities and Cash Flow Report for the quarter ending 30 June 2026. The company emphasized advances in developing its Photosoft™ platform technology, notably in cancer treatment and other diseases. Key achievements include the appointment of Dr. Colin Hopper as Clinical Advisor, which strengthens clinical governance, and an expanded partnership with SANGMYUNG Innovation Co., Ltd. in ophthalmology, potentially advancing Photosoft into the large wet age-related macular degeneration market. The financial highlights reveal a cash reserve of $592K at quarter's end, with significant cash inflows expected from R&D tax incentives. Invion also reported expansion in its clinical trial programs, including the INV043 non-melanoma skin cancer program. The report underscores a positive outlook with ongoing strategic collaborations and development milestones.
Key Points
  • Invion appointed Dr. Colin Hopper to strengthen clinical leadership.
  • Partnership with SANGMYUNG in ophthalmology for non-dilutive funding.
  • Progress in the INV043 skin cancer trial with positive safety and efficacy.
  • Expected cash inflow from R&D tax incentives.
  • End-of-quarter cash reserves stood at $592K.
  • Net cash inflow of $662K from financing activities.
  • Continued focus on Photosoft™ platform development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.